First-in-Class Drug Candidate Developed Through National Foundation for Cancer Research Funding Commences International Phase IIB Liver Cancer Clinical Trial
Gravida ultricies interdum risus adipiscing non. Ornare leo eu imperdiet.
AIM-HI Portfolio Company Profile: Yiviva
Gravida ultricies interdum risus adipiscing non. Ornare leo eu imperdiet.
Introducing the Women’s Venture Competition
Gravida ultricies interdum risus adipiscing non. Ornare leo eu imperdiet.
Portfolio Company of AIM-HI Accelerator Fund Receives Additional Investment and Recognition
Gravida ultricies interdum risus adipiscing non. Ornare leo eu imperdiet.
NFCR-Backed Technology Receives FDA’s Assent for Lymphoma Clinical Trials
Gravida ultricies interdum risus adipiscing non. Ornare leo eu imperdiet.
Applications Open for the AIM-HI Accelerator Fund’s Women’s Venture Competition
Gravida ultricies interdum risus adipiscing non. Ornare leo eu imperdiet.
AIM-HI Accelerator Fund CEO to Chair Prominent Investment Panel Discussion
Gravida ultricies interdum risus adipiscing non. Ornare leo eu imperdiet.
AIM-HI Accelerator Fund Portfolio Company Receives Virginia Catalyst Funding
Gravida ultricies interdum risus adipiscing non. Ornare leo eu imperdiet.
Disruptive Funding Model to Advance Innovations—A New Approach to Ending Cancer for Each and for All
Gravida ultricies interdum risus adipiscing non. Ornare leo eu imperdiet.
